文献速递消化系统肿瘤

改良氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂或S-1、伊立替康和奥沙利铂对比白蛋白结合型紫杉醇+吉西他滨治疗转移性或复发性胰腺癌(GENERATE,JCOG1611):一项随机、开放标签、II/III期试验

Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
PubMed 文献 · J Clin Oncol · 2025-07-28

该随机II/III期试验在日本45个中心纳入527例转移性或复发性胰腺癌患者,按1:1:1随机接受mFOLFIRINOX、S-IROX或白蛋白结合型紫杉醇+吉西他滨治疗。计划中期分析纳入426例,mFOLFIRINOX组和S-IROX组中位OS分别为14.0个月和13.6个月,均劣于白蛋白结合型紫杉醇+吉西他滨组的17.1个月,因无效提前终止。

要点

  • mFOLFIRINOX组中位OS 14.0个月(HR 1.31,95%CI 0.97-1.77),S-IROX组13.6个月(HR 1.35,95%CI 1.00-1.82),白蛋白结合型紫杉醇+吉西他滨组17.1个月。
  • 两试验组最终分析显示优效的预测概率均<1%,试验因无效终止。
  • mFOLFIRINOX组和S-IROX组3-4级厌食发生率分别为23.3%和27.5%,高于白蛋白结合型紫杉醇+吉西他滨组的5.0%。

核心结论

  • mFOLFIRINOX和S-IROX作为转移性或复发性胰腺癌一线治疗均未显示出优于白蛋白结合型紫杉醇+吉西他滨。

研究设计与样本

  • 随机、开放标签、II/III期试验,在日本45个中心进行。
  • 纳入年龄20-75岁、ECOG体能状态0或1、病理确诊的转移性或复发性胰腺癌患者,按1:1:1随机分配。
  • 共纳入527例患者,计划中期分析纳入426例。
  • 主要终点为总生存期(OS)。

主要发现

  • mFOLFIRINOX组中位OS为14.0个月(HR 1.31,95%CI 0.97-1.77),S-IROX组为13.6个月(HR 1.35,95%CI 1.00-1.82),白蛋白结合型紫杉醇+吉西他滨组为17.1个月。
  • mFOLFIRINOX组和S-IROX组最终分析显示优效的预测概率均<1%,试验因无效终止。
  • 3-4级厌食发生率:mFOLFIRINOX组23.3%,S-IROX组27.5%,白蛋白结合型紫杉醇+吉西他滨组5.0%。

关键数值与推荐

  • mFOLFIRINOX方案:奥沙利铂85 mg/m2持续2小时,伊立替康150 mg/m2持续90分钟,l-亚叶酸钙200 mg/m2持续2小时,均第1天每日一次;氟尿嘧啶2400 mg/m2持续46小时,第1-3天;每2周重复。
  • S-IROX方案:奥沙利铂85 mg/m2持续2小时,伊立替康150 mg/m2持续90分钟,第1天;S-1 80 mg/m2/天口服每日两次,第1-7天;每2周重复。
  • 白蛋白结合型紫杉醇+吉西他滨方案:白蛋白结合型紫杉醇125 mg/m2,吉西他滨1000 mg/m2,第1、8、15天,每4周重复。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity in a phase Ib trial in this population. Therefore, these three regimens were directly compared. METHODS: This randomized phase II/III trial was performed at 45 centers in Japan. Eligible patients age 20-75 years with an Eastern Cooperative Oncology Group performance status of 0 or 1 and pathologically confirmed metastatic or recurrent pancreatic cancer were randomly assigned (1:1:1) to receive mFOLFIRINOX (oxaliplatin 85 mg/m2 over 2 hours, irinotecan 150 mg/m2 over 90 minutes, l-leucovorin 200 mg/m2 over 2 hours, each once daily on day 1, and fluorouracil 2,400 mg/m2 over 46 hours on days 1-3, every 2 weeks), S-IROX (oxaliplatin 85 mg/m2 over 2 hours, irinotecan 150 mg/m2 over 90 minutes on day 1, and S-1 80 mg/m2/day administered orally twice daily on days 1-7, every 2 weeks), or nab-paclitaxel (125 mg/m2) + gemcitabine (1,000 mg/m2) on days 1, 8, and 15 every 4 weeks. The primary end point was overall survival (OS). RESULTS: A total of 527 patients were enrolled, with 426 included in the planned interim analysis. The median OS was 14.0 months (hazard ratio [HR], 1.31 [95% CI, 0.97 to 1.77]) and 13.6 months (HR, 1.35 [95% CI, 1.00 to 1.82]) in the mFOLFIRINOX and S-IROX groups, respectively, as compared with 17.1 months in the nab-paclitaxel + gemcitabine group. The predictive probability of achieving superiority in the final analysis was <1% in both groups. Thus, the trial was terminated owing to its futility. Grade 3 to 4 anorexia was more frequent in the mFOLFIRINOX (23.3%) and S-IROX (27.5%) groups than in the nab-paclitaxel + gemcitabine group (5.0%). CONCLUSION: Neither mFOLFIRINOX nor S-IROX appeared to be superior compared with nab-paclitaxel + gemcitabine as the first-line treatment for metastatic or recurrent pancreatic cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ohba A, Ozaka M, Mizusawa J, et al. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. J Clin Oncol. 2025. PMID: 40720715. doi:10.1200/JCO.24.00936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。